Efficacy of alectinib for ALK-positive NSCLC brain metastases
10.3969/j.issn.1000-8179.2020.13.344
- VernacularTitle: 阿来替尼治疗 ALK 基因融合重排 NSCLC 脑转移瘤的临床疗效分析
- Author:
Qiang YIN
1
Author Information
1. Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer
- Publication Type:Journal Article
- Keywords:
Alectinib;
Anaplastic lymphoma kinase (ALK);
Brain metastases;
Non-small cell lung cancer (NSCLC)
- From:
Chinese Journal of Clinical Oncology
2020;47(13):661-665
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effect of alectinib in the treatment of brain metastases from anaplastic lymphoma kinase(ALK)positive non-small cell lung cancer (NSCLC). Methods: Thirty-four cases of ALK-positive NSCLC in Tianjin Medical University Cancer Institute and Hospital, between August 2016 to October 2019, were retrospectively analyzed. Thirteen cases received first-line single drug therapy (600 mg PO bid) of Alectinib. 7 cases (53.8%) were male, 6 cases were female (46.2%), the median age was 51 (35-72). The Kaplan-Meier method was used to examine progression-free survival (PFS). Results: The median progression-free survival (mPFS) of the alectinib group was 24.5 months, and the adverse drug reactions were mild. Conclusions: The use of alectinibas first-line treatment after the local treatment of measurable intracranial lesions significantly increased the PFS of patients with brain metastases from ALK-positive NSCLC.
